PubMed:26747427
Annnotations
Glycan-Motif
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 69-76 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T2 | 384-390 | https://glytoucan.org/Structures/Glycans/G82576YO | denotes | fucose |
T3 | 448-455 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T4 | 448-455 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T5 | 665-672 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T6 | 832-839 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T7 | 963-970 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T8 | 990-997 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T9 | 990-997 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T10 | 1063-1070 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T11 | 1063-1070 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T12 | 1095-1102 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T13 | 1095-1102 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T14 | 1215-1222 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T15 | 1268-1275 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T16 | 1439-1446 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T17 | 1645-1651 | https://glytoucan.org/Structures/Glycans/G82576YO | denotes | fucose |
T18 | 1693-1700 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T19 | 1775-1782 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 69-76 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T2 | 384-390 | Glycan_Motif | denotes | fucose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G82576YO |
T3 | 448-455 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
T5 | 665-672 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T6 | 832-839 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T7 | 963-970 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T8 | 990-997 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
T10 | 1063-1070 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
T12 | 1095-1102 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
T14 | 1215-1222 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T15 | 1268-1275 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T16 | 1439-1446 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T17 | 1645-1651 | Glycan_Motif | denotes | fucose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G82576YO |
T18 | 1693-1700 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
T19 | 1775-1782 | Glycan_Motif | denotes | mannose | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 69-76 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T2 | 384-390 | https://glytoucan.org/Structures/Glycans/G82576YO | denotes | fucose |
T3 | 448-455 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T4 | 448-455 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T5 | 665-672 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T6 | 832-839 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T7 | 963-970 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T8 | 990-997 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T9 | 990-997 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T10 | 1063-1070 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T11 | 1063-1070 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T12 | 1095-1102 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T13 | 1095-1102 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T14 | 1215-1222 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T15 | 1268-1275 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T16 | 1439-1446 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T17 | 1645-1651 | https://glytoucan.org/Structures/Glycans/G82576YO | denotes | fucose |
T18 | 1693-1700 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
T19 | 1775-1782 | https://glytoucan.org/Structures/Glycans/G70323CJ | denotes | mannose |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-135 | Sentence | denotes | Comparison of biological activities of human antithrombins with high-mannose or complex- type nonfucosylated N-linked oligosaccharides. |
TextSentencer_T2 | 136-286 | Sentence | denotes | The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. |
TextSentencer_T3 | 287-473 | Sentence | denotes | Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin binding affinity. |
TextSentencer_T4 | 474-614 | Sentence | denotes | In human plasma, AT circulates as a mixture of the α-form bearing four oligosaccharides and the β-form lacking an oligosaccharide at Asn135. |
TextSentencer_T5 | 615-758 | Sentence | denotes | However, it remains unclear how the immature high-mannose-type oligosaccharides produced by mammalian cells affect biological activities of AT. |
TextSentencer_T6 | 759-858 | Sentence | denotes | Here, we succeeded in directly comparing the activities between the high-mannose and complex-types. |
TextSentencer_T7 | 859-1015 | Sentence | denotes | Interestingly, although there were no substantial differences in thrombin inhibitory activity, the high-mannose-type showed higher heparin binding affinity. |
TextSentencer_T8 | 1016-1228 | Sentence | denotes | The anticoagulant activities were increased by heparin and correlated with the heparin binding affinity, resulting in the strongest anticoagulant activity being displayed in the β-form with the high-mannose-type. |
TextSentencer_T9 | 1229-1342 | Sentence | denotes | In pharmacokinetic profiling, the high-mannose-type showed a much shorter plasma half-life than the complex-type. |
TextSentencer_T10 | 1343-1539 | Sentence | denotes | The β-form was found to have a prolonged plasma half-life compared with the α-form for the high-mannose-type; conversely, the α-form showed a longer half-life than the β-form for the complex-type. |
TextSentencer_T11 | 1540-1740 | Sentence | denotes | The present study highlights that AT physiological activities are strictly controlled not only by a core fucose at the reducing end but also by the high-mannose-type structures at the nonreducing end. |
TextSentencer_T12 | 1741-1913 | Sentence | denotes | The β-form with the immature high-mannose-type appears to function as a more potent anticoagulant than the AT typically found in human plasma, once it emerges in the blood. |
T1 | 0-135 | Sentence | denotes | Comparison of biological activities of human antithrombins with high-mannose or complex- type nonfucosylated N-linked oligosaccharides. |
T2 | 136-286 | Sentence | denotes | The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. |
T3 | 287-473 | Sentence | denotes | Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin binding affinity. |
T4 | 474-614 | Sentence | denotes | In human plasma, AT circulates as a mixture of the α-form bearing four oligosaccharides and the β-form lacking an oligosaccharide at Asn135. |
T5 | 615-758 | Sentence | denotes | However, it remains unclear how the immature high-mannose-type oligosaccharides produced by mammalian cells affect biological activities of AT. |
T6 | 759-858 | Sentence | denotes | Here, we succeeded in directly comparing the activities between the high-mannose and complex-types. |
T7 | 859-1015 | Sentence | denotes | Interestingly, although there were no substantial differences in thrombin inhibitory activity, the high-mannose-type showed higher heparin binding affinity. |
T8 | 1016-1228 | Sentence | denotes | The anticoagulant activities were increased by heparin and correlated with the heparin binding affinity, resulting in the strongest anticoagulant activity being displayed in the β-form with the high-mannose-type. |
T9 | 1229-1342 | Sentence | denotes | In pharmacokinetic profiling, the high-mannose-type showed a much shorter plasma half-life than the complex-type. |
T10 | 1343-1539 | Sentence | denotes | The β-form was found to have a prolonged plasma half-life compared with the α-form for the high-mannose-type; conversely, the α-form showed a longer half-life than the β-form for the complex-type. |
T11 | 1540-1740 | Sentence | denotes | The present study highlights that AT physiological activities are strictly controlled not only by a core fucose at the reducing end but also by the high-mannose-type structures at the nonreducing end. |
T12 | 1741-1913 | Sentence | denotes | The β-form with the immature high-mannose-type appears to function as a more potent anticoagulant than the AT typically found in human plasma, once it emerges in the blood. |
T1 | 0-135 | Sentence | denotes | Comparison of biological activities of human antithrombins with high-mannose or complex- type nonfucosylated N-linked oligosaccharides. |
T2 | 136-286 | Sentence | denotes | The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. |
T3 | 287-473 | Sentence | denotes | Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin binding affinity. |
T4 | 474-614 | Sentence | denotes | In human plasma, AT circulates as a mixture of the α-form bearing four oligosaccharides and the β-form lacking an oligosaccharide at Asn135. |
T5 | 615-758 | Sentence | denotes | However, it remains unclear how the immature high-mannose-type oligosaccharides produced by mammalian cells affect biological activities of AT. |
T6 | 759-858 | Sentence | denotes | Here, we succeeded in directly comparing the activities between the high-mannose and complex-types. |
T7 | 859-1015 | Sentence | denotes | Interestingly, although there were no substantial differences in thrombin inhibitory activity, the high-mannose-type showed higher heparin binding affinity. |
T8 | 1016-1228 | Sentence | denotes | The anticoagulant activities were increased by heparin and correlated with the heparin binding affinity, resulting in the strongest anticoagulant activity being displayed in the β-form with the high-mannose-type. |
T9 | 1229-1342 | Sentence | denotes | In pharmacokinetic profiling, the high-mannose-type showed a much shorter plasma half-life than the complex-type. |
T10 | 1343-1539 | Sentence | denotes | The β-form was found to have a prolonged plasma half-life compared with the α-form for the high-mannose-type; conversely, the α-form showed a longer half-life than the β-form for the complex-type. |
T11 | 1540-1740 | Sentence | denotes | The present study highlights that AT physiological activities are strictly controlled not only by a core fucose at the reducing end but also by the high-mannose-type structures at the nonreducing end. |
T12 | 1741-1913 | Sentence | denotes | The β-form with the immature high-mannose-type appears to function as a more potent anticoagulant than the AT typically found in human plasma, once it emerges in the blood. |
Glycosmos6-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1907-1912 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
T2 | 1907-1912 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
GlycoBiology-FMA
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
_T1 | 69-76 | FMAID:196796 | denotes | mannose |
_T2 | 69-76 | FMAID:82801 | denotes | mannose |
_T3 | 118-134 | FMAID:82742 | denotes | oligosaccharides |
_T4 | 118-134 | FMAID:196731 | denotes | oligosaccharides |
_T5 | 166-182 | FMAID:82742 | denotes | oligosaccharides |
_T6 | 166-182 | FMAID:196731 | denotes | oligosaccharides |
_T7 | 325-341 | FMAID:82742 | denotes | oligosaccharides |
_T8 | 325-341 | FMAID:196731 | denotes | oligosaccharides |
_T9 | 384-390 | FMAID:196784 | denotes | fucose |
_T10 | 384-390 | FMAID:82790 | denotes | fucose |
_T11 | 448-455 | FMAID:82839 | denotes | heparin |
_T12 | 448-455 | FMAID:167420 | denotes | heparin |
_T13 | 483-489 | FMAID:162307 | denotes | plasma |
_T14 | 545-561 | FMAID:196731 | denotes | oligosaccharides |
_T15 | 545-561 | FMAID:82742 | denotes | oligosaccharides |
_T16 | 588-603 | FMAID:196731 | denotes | oligosaccharide |
_T17 | 588-603 | FMAID:82742 | denotes | oligosaccharide |
_T18 | 665-672 | FMAID:82801 | denotes | mannose |
_T19 | 665-672 | FMAID:196796 | denotes | mannose |
_T20 | 678-694 | FMAID:82742 | denotes | oligosaccharides |
_T21 | 678-694 | FMAID:196731 | denotes | oligosaccharides |
_T22 | 717-722 | FMAID:169002 | denotes | cells |
_T23 | 717-722 | FMAID:68646 | denotes | cells |
_T24 | 832-839 | FMAID:82801 | denotes | mannose |
_T25 | 832-839 | FMAID:196796 | denotes | mannose |
_T26 | 897-908 | FMAID:188924 | denotes | substantial |
_T27 | 963-970 | FMAID:196796 | denotes | mannose |
_T28 | 963-970 | FMAID:82801 | denotes | mannose |
_T29 | 990-997 | FMAID:167420 | denotes | heparin |
_T30 | 990-997 | FMAID:82839 | denotes | heparin |
_T31 | 1063-1070 | FMAID:82839 | denotes | heparin |
_T32 | 1063-1070 | FMAID:167420 | denotes | heparin |
_T33 | 1095-1102 | FMAID:82839 | denotes | heparin |
_T34 | 1095-1102 | FMAID:167420 | denotes | heparin |
_T35 | 1215-1222 | FMAID:82801 | denotes | mannose |
_T36 | 1215-1222 | FMAID:196796 | denotes | mannose |
_T37 | 1268-1275 | FMAID:82801 | denotes | mannose |
_T38 | 1268-1275 | FMAID:196796 | denotes | mannose |
_T39 | 1303-1309 | FMAID:162307 | denotes | plasma |
_T40 | 1384-1390 | FMAID:162307 | denotes | plasma |
_T41 | 1439-1446 | FMAID:82801 | denotes | mannose |
_T42 | 1439-1446 | FMAID:196796 | denotes | mannose |
_T43 | 1645-1651 | FMAID:82790 | denotes | fucose |
_T44 | 1645-1651 | FMAID:196784 | denotes | fucose |
_T45 | 1693-1700 | FMAID:196796 | denotes | mannose |
_T46 | 1693-1700 | FMAID:82801 | denotes | mannose |
_T47 | 1775-1782 | FMAID:196796 | denotes | mannose |
_T48 | 1775-1782 | FMAID:82801 | denotes | mannose |
_T49 | 1876-1882 | FMAID:162307 | denotes | plasma |
_T50 | 1907-1912 | FMAID:256053 | denotes | blood |
uniprot-mouse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 209-211 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
T2 | 293-295 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
T3 | 491-493 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
T4 | 755-757 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
T5 | 1574-1576 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
T6 | 1848-1850 | http://www.uniprot.org/uniprot/Q8VHK8 | denotes | AT |
GlycoBiology-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 717-722 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 242-264 | http://purl.obolibrary.org/obo/GO_0050819 | denotes | anticoagulant activity |
T2 | 1020-1044 | http://purl.obolibrary.org/obo/GO_0050819 | denotes | anticoagulant activities |
GO-MF
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 448-463 | http://purl.obolibrary.org/obo/GO_0008201 | denotes | heparin binding |
T2 | 990-1005 | http://purl.obolibrary.org/obo/GO_0008201 | denotes | heparin binding |
T3 | 1095-1110 | http://purl.obolibrary.org/obo/GO_0008201 | denotes | heparin binding |
T4 | 456-463 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
T5 | 998-1005 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
T6 | 1103-1110 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
T7 | 456-463 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
T8 | 998-1005 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
T9 | 1103-1110 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
T10 | 456-463 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
T11 | 998-1005 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
T12 | 1103-1110 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
T13 | 456-463 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
T14 | 998-1005 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
T15 | 1103-1110 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
GO-CC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 379-383 | http://purl.obolibrary.org/obo/GO_0019013 | denotes | core |
T2 | 1640-1644 | http://purl.obolibrary.org/obo/GO_0019013 | denotes | core |
T3 | 717-722 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1907-1912 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
GlycoBiology-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1907-1912 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
T2 | 1907-1912 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 1907-1912 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
GlycoBiology-Motifs
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 64-76 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T2 | 660-672 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T3 | 827-839 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T4 | 958-970 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T5 | 1210-1222 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T6 | 1263-1275 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T7 | 1434-1446 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T8 | 1688-1700 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T9 | 1770-1782 | http://rdf.glycoinfo.org/glycan/G00028MO | denotes | high-mannose |
T10 | 448-455 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
T11 | 990-997 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
T12 | 1063-1070 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
T13 | 1095-1102 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
Anatomy-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 1907-1912 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000083|http://purl.obolibrary.org/obo/MAT_0000315 |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 39-44 | OrganismTaxon | denotes | human | 9606 |
T2 | 287-292 | OrganismTaxon | denotes | Human | 9606 |
T3 | 477-482 | OrganismTaxon | denotes | human | 9606 |
T4 | 1870-1875 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 483-489 | Body_part | denotes | plasma | http://purl.obolibrary.org/obo/UBERON_0001969 |
T2 | 1303-1309 | Body_part | denotes | plasma | http://purl.obolibrary.org/obo/UBERON_0001969 |
T3 | 1384-1390 | Body_part | denotes | plasma | http://purl.obolibrary.org/obo/UBERON_0001969 |
T4 | 1876-1882 | Body_part | denotes | plasma | http://purl.obolibrary.org/obo/UBERON_0001969 |
T5 | 1907-1912 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |